SAN DIEGO, March 20, 2017 /PRNewswire/ -- Biocept, Inc.
(NASDAQ: BIOC), a leading commercial provider of liquid biopsy
tests designed to provide physicians with clinically actionable
information to improve the outcomes of cancer patients, announces a
revised time for its presentation at the 27th Annual
Oppenheimer Healthcare Conference. David
Moskowitz, Vice President of Strategy and Corporate
Communications, is now scheduled to present a corporate overview on
Wednesday, March 22, 2017 at
1:00 p.m. Eastern time (10:00 a.m. Pacific time). The conference is
being held at The Westin New York Grand Central in New York City.
A live webcast of the corporate presentation will be available
on the Company's website at ir.biocept.com. A replay of the
presentations will be available for 90 days.
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. For additional
information, please visit www.biocept.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biocept-announces-revised-presentation-time-at-the-27th-annual-oppenheimer-healthcare-conference-300425946.html
SOURCE Biocept, Inc.